Gene synthesis market seen reaching $5.9B by 2031

By AI, Created 8:50 AM UTC, May 25, 2026, /AGP/ – Allied Market Research projects the global gene synthesis market will grow from $1.11 billion in 2021 to $5.9 billion by 2031, driven by synthetic biology, gene editing and personalized medicine. The report points to rising demand in healthcare and research, even as ethical, regulatory and cost barriers remain.

Why it matters: - Gene synthesis is becoming a core tool for drug discovery, vaccine development, genetic research and agricultural biotechnology. - The market’s projected rise reflects growing demand for technologies that can speed up therapy development and support more targeted medicine. - The report also signals a larger shift toward automation and high-throughput biology across healthcare and life sciences.

What happened: - Allied Market Research projected the global gene synthesis market will reach $5.9 billion by 2031. - The market was valued at $1.11 billion in 2021. - The forecast implies 18.4% CAGR from 2022 to 2031. - The report was published from Portland, Oregon, on May 25, 2026. - The study said the market is expanding across synthetic biology, genetic engineering and biotechnology. - Request the sample report.

The details: - Gene synthesis is the artificial creation of DNA sequences in laboratories. - The technology lets researchers design and modify genetic material for specific applications. - The report identified synthetic biology applications as a major growth driver. - Personalized medicine is also lifting demand for gene synthesis technologies. - DNA sequencing and gene editing tools such as CRISPR are accelerating market growth. - Automation and high-throughput synthesis are improving efficiency and lowering costs. - The report said gene synthesis is used in drug discovery, vaccine development, genetic research and therapies for cancer and genetic disorders. - In agriculture, gene synthesis supports genetically modified crops with better yield and resistance to pests and disease. - Services hold the dominant share by product type. - Healthcare and research applications dominate by application. - Pharmaceutical companies, biotechnology firms and academic institutions are key end users. - North America leads the market. - Asia-Pacific is expected to grow rapidly. - Emerging markets present growth opportunities because of rising biotechnology investment and healthcare infrastructure spending. - The report also highlighted ethical concerns, biosecurity questions, regulatory issues and high equipment costs as market restraints.

Between the lines: - The market forecast suggests gene synthesis is moving from a specialized research capability toward a broader commercial platform. - Strong demand is likely where companies can pair synthesis with sequencing, editing and automated workflows. - The biggest friction points remain policy, safety oversight and the cost of advanced systems, especially in developing regions.

What’s next: - Allied Market Research expects continued expansion through 2031 as biotech investment and personalized medicine adoption grow. - The report points to emerging markets as a key source of future demand. - Further gains will likely depend on lower costs, better automation and clearer regulatory frameworks. - Read the market overview.

The bottom line: - Gene synthesis is on track for fast growth, but the biggest upside will depend on whether the industry can scale safely and affordably.